OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today provided the following scientific and commercial update on its technology..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, announced today the launch of its award winning SlimBiome® in Nutri-Bites® with its US..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has entered into a production and commercialisation..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces successful human taste studies in its SweetBiotix® product development programmes. The Company..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skin care, announces that it has had an abstract accepted for presentation at ProBiota..

OptiBiotix Health plc (LON: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced today that further to the announcement dated 5 December 2017, Richard Colin..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that subject to the completion of normal regulatory due..

Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it intends to convene a General Meeting (“GM”)..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care provides the following product development and commercial update on its SlimBiome®..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has entered into a manufacturing and supply..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it will be presenting research data on its..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has entered into a three year supply..

Medications and treatment plans are designed based on averages, but not everyone is average; a treatment that works for one might not work for another. In the new wave of..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, and diabetes announced today the successful launch of its SlimBiome® and LPLDL® products at Supply Side..

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provided today the following technical, regulatory and commercial update on its..

OptiBiotix Health Plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced today that it has signed a Memorandum of Understanding (“MoU”) with Bened..